Effect of Sinitang Combined with Targeted Therapy and Immunotherapy on Enterohepatic Circulation of Bile Acid in Patients with Liver Cancer
10.13422/j.cnki.syfjx.20261325
- VernacularTitle:四逆汤联合靶免治疗对肝癌患者胆汁酸肝肠循环的影响
- Author:
Yi SHI
1
;
Yalan QIU
2
;
Mengmeng CAI
3
;
Peipei HUANG
4
;
Jingdong GAO
1
;
Ting CHEN
1
Author Information
1. Suzhou Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Suzhou 215000,China
2. Kunshan Hospital of Chinese Medicine, Kunshan 215300,China
3. The Fourth Affiliated Hospital of Soochow University, Suzhou 215000,China
4. Nanjing University of Chinese Medicine, Nanjing 210023,China
- Publication Type:Journal Article
- Keywords:
Sinitang;
liver cancer;
intestinal flora;
bile acid;
cholesterol metabolism;
16S rDNA
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(24):120-128
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy of Sinitang combined with lenvatinib mesylate and sintilizumab in treating liver cancer and the effects on the cholesterol metabolism and intestinal flora structure in the patients, thus preliminarily exploring the regulatory effect on hepatoenteric circulation of bile acid. MethodsEighty liver cancer patients treated in Suzhou Hospital of Traditional Chinese Medicine were selected and randomly allocated to control and observation groups, with 40 patients in each group. The control group was treated with lenvatinib mesylate combined with sintilimab, and the observation group additionally received Sinitang granules for three months. The Karnofsky Performance Status (KPS) score, traditional Chinese medicine (TCM) syndrome efficacy, TCM syndrome score, and computed tomography/magnetic resonance imaging (CT/MRI) imaging results of the two groups before and after treatment were compared. The serum levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and total bile acid (TBA) were assayed. The 16S rDNA sequencing technique was used to detect the changes of intestinal flora structure characteristics and the correlation between differential taxa and TBA in the two groups before and after treatment. ResultsAfter treatment, the KPS scores of the two groups increased (P<0.05,P<0.01), and the change was more pronounced in the observation group (P<0.01). Following treatment, TCM symptom scores in the observation group declined (P<0.01). The total response rate of TCM syndrome alleviation in the observation group was 82.50%(33/40), exceeding that (55.00%, 22/40) of the control group (χ2=7.040, P<0.05). Post-treatment CT/MRI findings in the observation group tended to be better than those in the control group, although the inter-group difference did not reach statistical significance. After treatment, the observation group showed increases in the number of gut microbial taxa at the phylum, order, family, genus, and species levels (P<0.05). In addition, the observation group exhibited declined serum TC, TG, and LDL-C levels (P<0.05) and TBA level (P<0.01), whereas the HDL-C level increased slightly. After Sinitang treatment, the diversity of intestinal flora in patients with liver cancer increased. The relative abundance of Comamonas decreased, and that of f__Planococcaceae_Unclassified, differed significantly before and after treatment,while f__Oscillospiraceae_Unclassified, and Christensenellaceae_R-7_group increased (P<0.05). The differential bacterial species demonstrated a strong correlation with TBA (P<0.05). ConclusionSinitang combined with targeted therapy and immunotherapy can improve the clinical status of patients with liver cancer and regulate cholesterol metabolism and intestinal flora structure by regulating the enterohepatic circulation of bile acid.